The MHRA Has Approved a Stronger Wegovy — Here Is What That Actually Means

The misconception worth clearing up first: 7.2mg is not a new drug

A lot of the coverage around this approval has left people wondering whether Wegovy has been replaced, reformulated, or superseded by something entirely different. It has not. Semaglutide is still semaglutide. What the MHRA approved on 14 April 2026 was a new maximum dose and a new pen format, a single pre-set injection that delivers 7.2mg per week, with an auto-dosing mechanism, a built-in covered needle, and a lock that activates after use. The medicine inside is the same GLP-1 receptor agonist that has been used in the UK since Wegovy's original approval. The full history of Wegovy's licensing in the UK shows a medicine that has been incrementally refined rather than replaced.

Why does the distinction matter? Because patients already established on Wegovy do not need to restart from scratch, and people comparing this to a brand-new product may be drawing the wrong conclusions about switching or eligibility. The approval extends what was already there, it does not replace it.

The UK was also notably ahead here. As of the approval date, this was the first such authorisation in Europe, according to the MHRA's announcement on GOV.UK. That is worth knowing, because it means guidance, SmPCs and clinical protocols in other countries may not yet reflect this dose.

What the trial evidence shows at 7.2mg, and what it does not promise

The clinical picture for the 7.2mg dose is genuinely encouraging. Trial data reported approximately 20.7% average weight loss over 72 weeks, a meaningful step up from the roughly 15% seen with the 2.4mg maintenance dose in the STEP 1 trial. For context on where that sits relative to other licensed options, the comparison between semaglutide and other weight-loss medicines is a useful reference point.

The gap between this result and tirzepatide's highest-dose figures (around 20 to 21% at 15mg in SURMOUNT-1) is now considerably narrower than it was. That matters to anyone trying to weigh up their options. It does not, however, mean 7.2mg will produce those results for every patient. Clinical trial averages describe populations, not individuals. Some people will lose more; some less. A prescriber assessing your full medical picture is the only reliable guide to realistic expectations.

One practical note on timing: if you are planning to start or change treatment, it is worth factoring in the consultation and dispatch window. Orders placed by midday on a working day are reviewed the same day and dispatched once approved, useful to know around bank holidays or if you are ordering before a break. Details on how that process works are covered on the Wegovy consultation page.

Who the 7.2mg approval applies to, and the limits the MHRA set

The new pen is licensed for adults with obesity defined as a BMI of 30 or above. That is a specific boundary. The 7.2mg dose does not carry approval for people with a BMI below 30 who might otherwise qualify for lower-dose Wegovy on the basis of a weight-related condition, that pathway uses the existing licensed doses. The 7.2mg dose also does not carry the cardiovascular indication that covers certain Wegovy patients at higher cardiac risk; that indication remains tied to the existing formulation and its separate evidence base.

Titration still begins at 0.25mg. The route to 7.2mg runs through the same escalating schedule (0.25mg, 0.5mg, 1.0mg, 1.7mg, 2.4mg) before reaching the new maximum, with each step guided by a prescriber at roughly four-week intervals. The semaglutide medicine page covers how that schedule works in practice.

For patients already on the 2.4mg dose who are clinically suitable, the question of whether to progress to 7.2mg is one for their prescriber, not a decision to make unilaterally. Evidence of ongoing response, tolerability at the current dose, and individual health factors all feed into it. The comparison with other licensed weight-loss injectables may also help frame where 7.2mg sits in the broader landscape.

What this means in practice for people considering Wegovy now

The approval of a 7.2mg option changes the ceiling for what semaglutide can offer, but it does not change the fundamental structure of accessing it. Wegovy is a prescription-only medicine. The NHS semaglutide guidance is clear that assessment by a prescriber is required before treatment begins, and that applies at every dose level, including the new maximum.

Whether specific doses or pen formats are available through a given provider is confirmed at consultation rather than assumed. What a legitimate service offers is a thorough clinical review, identity verification, and a supply chain traceable to authorised UK distributors. The about us page explains how nume's pharmacy operates within that framework, GPhC-registered, MHRA-regulated, with every consultation personally reviewed by a GPhC-registered Independent Prescriber on the day it is submitted.

If you are trying to work out whether you qualify for treatment, or which licensed option suits your circumstances, a free consultation is the straightforward next step. Check your eligibility with our prescribers, there is no commitment, and your consultation is reviewed the same day.